Thromb Haemost 1978; 39(03): 624-630
DOI: 10.1055/s-0038-1646736
Original Article
Schattauer GmbH Stuttgart

Immunologic Studies of Antithrombin III Heparin Cofactor in the Newborn

W E Hathaway
The Department of Pediatrics, University of Colorado Medical Center, Denver, Colorado, 80262, U.S.A.
,
L L Neumann
The Department of Pediatrics, University of Colorado Medical Center, Denver, Colorado, 80262, U.S.A.
,
C A Borden
The Department of Pediatrics, University of Colorado Medical Center, Denver, Colorado, 80262, U.S.A.
,
L J Jacobson
The Department of Pediatrics, University of Colorado Medical Center, Denver, Colorado, 80262, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 09 November 1977

Accepted 24 December 1977

Publication Date:
12 July 2018 (online)

Preview

Summary

Serial quantitative immunoelectrophoretic (IE) measurements of antithrombin III heparin cofactor (AT III) were made in groups of well and sick newborn infants classified by gestational age. Collection methods (venous vs. capillary) did not influence the results; serum IE measurements were comparable to AT III activity by a clotting method. AT III is gestational age-dependent, increasing from 28.7% of normal adult values at 28-32 weeks to 50.9% at 37-40 weeks, and shows a gradual increase to term infant levels (57.4%) by 3-4 weeks of age. Infants with the respiratory distress syndrome (RDS) show lower levels of AT III in the 33-36 week group, 22% vs. 44% and in the 37-40 week group, 33.6% vs. 50.9%, than prematures without RDS. Infants of 28-32 week gestational age had only slight differences, RDS = 24%, non-RDS = 28.7%. The lowest levels of AT III were seen in patients with RDS complicated by disseminated intravascular coagulation and those with necrotizing enterocolitis. Crossed IE on representative infants displayed a consistent pattern which was identical to adult controls except for appropriate decreases in the amplitude of the peaks. The thrombotic complications seen in the sick preterm infant may be related to the low levels of AT III.